<PubmedArticle>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">19891806</PMID>
<DateCompleted>
<Year>2010</Year>
<Month>10</Month>
<Day>14</Day>
</DateCompleted>
<DateRevised>
<Year>2018</Year>
<Month>11</Month>
<Day>13</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1469-8978</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>40</Volume>
<Issue>8</Issue>
<PubDate>
<Year>2010</Year>
<Month>Aug</Month>
</PubDate>
</JournalIssue>
<Title>Psychological medicine</Title>
<ISOAbbreviation>Psychol Med</ISOAbbreviation>
</Journal>
<ArticleTitle>Can pharmacotherapists be too supportive? A process study of active medication and placebo in the treatment of depression.</ArticleTitle>
<Pagination>
<MedlinePgn>1379-87</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1017/S0033291709991553</ELocationID>
<Abstract>
<AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">This study examined therapist-patient interactions during clinical management with antidepressant medication and pill-placebo.</AbstractText>
<AbstractText Label="METHOD" NlmCategory="METHODS">The sample consisted of 80 patients on active medication and 40 patients in a pill-placebo condition from a randomized controlled trial for moderate to severe depression. Pharmacotherapist-patient interactions were characterized using observer ratings of the therapeutic alliance, pharmacotherapist-offered facilitative conditions, pharmacotherapist adherence to clinical management treatment guidelines and pharmacotherapist competence. Patients, therapists and raters were blind to treatment condition and outcome.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">Provision of greater non-specific support (facilitative conditions) in early sessions predicted less subsequent improvement in depressive symptoms for patients receiving pill-placebo but not those receiving active medications, for which none of the process ratings predicted subsequent change. Early symptom change predicted later alliance and adherence in both conditions and therapist competence in the active condition.</AbstractText>
<AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Higher levels of support in early sessions predict poorer subsequent response among placebo patients. It remains unclear whether patients who are likely to be refractory elicit greater non-specific support or whether the provision of such support has a deleterious effect in unmedicated patients. Differences in treatment process variables between conditions late in treatment are likely to be largely a consequence of symptom relief produced by active medications.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Strunk</LastName>
<ForeName>D R</ForeName>
<Initials>DR</Initials>
<AffiliationInfo>
<Affiliation>Department of Psychology, Ohio State University, Columbus, OH 43210, USA. strunk.20@osu.edu</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Stewart</LastName>
<ForeName>M O</ForeName>
<Initials>MO</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Hollon</LastName>
<ForeName>S D</ForeName>
<Initials>SD</Initials>
</Author>
<Author ValidYN="Y">
<LastName>DeRubeis</LastName>
<ForeName>R J</ForeName>
<Initials>RJ</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Fawcett</LastName>
<ForeName>J</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Amsterdam</LastName>
<ForeName>J D</ForeName>
<Initials>JD</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Shelton</LastName>
<ForeName>R C</ForeName>
<Initials>RC</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>T32-MH18921</GrantID>
<Acronym>MH</Acronym>
<Agency>NIMH NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>P30 HD015052</GrantID>
<Acronym>HD</Acronym>
<Agency>NICHD NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>P30HD15052</GrantID>
<Acronym>HD</Acronym>
<Agency>NICHD NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>T32 MH018921</GrantID>
<Acronym>MH</Acronym>
<Agency>NIMH NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R10 MH055875</GrantID>
<Acronym>MH</Acronym>
<Agency>NIMH NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>MH55875 R10</GrantID>
<Acronym>MH</Acronym>
<Agency>NIMH NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>MH50129 R10</GrantID>
<Acronym>MH</Acronym>
<Agency>NIMH NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D003160">Comparative Study</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016448">Multicenter Study</PublicationType>
<PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2009</Year>
<Month>11</Month>
<Day>06</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>Psychol Med</MedlineTA>
<NlmUniqueID>1254142</NlmUniqueID>
<ISSNLinking>0033-2917</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D018687">Antidepressive Agents, Second-Generation</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>41VRH5220H</RegistryNumber>
<NameOfSubstance UI="D017374">Paroxetine</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018687">Antidepressive Agents, Second-Generation</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D003131">Combined Modality Therapy</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D003865">Depressive Disorder, Major</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005500">Follow-Up Studies</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019983">Guideline Adherence</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017374">Paroxetine</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D010595">Pharmacists</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011361">Professional Competence</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D011369">Professional-Patient Relations</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData>
<History>
<PubMedPubDate PubStatus="entrez">
<Year>2009</Year>
<Month>11</Month>
<Day>7</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed">
<Year>2009</Year>
<Month>11</Month>
<Day>7</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline">
<Year>2010</Year>
<Month>10</Month>
<Day>15</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
<ArticleId IdType="pubmed">19891806</ArticleId>
<ArticleId IdType="pii">S0033291709991553</ArticleId>
<ArticleId IdType="doi">10.1017/S0033291709991553</ArticleId>
<ArticleId IdType="pmc">PMC3743545</ArticleId>
<ArticleId IdType="mid">NIHMS259401</ArticleId>
</ArticleIdList>
<ReferenceList>
<Reference>
<Citation>J Consult Clin Psychol. 2000 Jun;68(3):438-50</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">10883561</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Consult Clin Psychol. 2000 Dec;68(6):1027-32</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">11142536</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Psychol Bull. 1979 Mar;86(2):420-8</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">18839484</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Psychopharmacol Bull. 1987;23(2):309-24</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">3303100</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Arch Gen Psychiatry. 1988 Aug;45(8):742-7</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">3395203</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Consult Clin Psychol. 1992 Feb;60(1):73-9</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">1556289</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Consult Clin Psychol. 1993 Aug;61(4):561-73</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">8370852</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Consult Clin Psychol. 1996 Jun;64(3):532-9</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">8698947</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Consult Clin Psychol. 1996 Feb;64(1):81-7</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">8907087</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Consult Clin Psychol. 1997 Jun;65(3):510-4</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">9170775</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Clin Psychiatry. 1997 May;58(5):196-204</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">9184613</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Consult Psychol. 1957 Apr;21(2):95-103</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">13416422</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Psychol Bull. 1959 Mar;56(2):81-105</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">13634291</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Neurol Neurosurg Psychiatry. 1960 Feb;23:56-62</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">14399272</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Arch Gen Psychiatry. 2005 Apr;62(4):409-16</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">15809408</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Drug Alcohol Depend. 2008 Jun 1;95(3):230-6</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">18329827</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Clin Psychol Rev. 2008 Oct;28(7):1167-87</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">18538907</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</PubmedArticle>